Education
About Us
Working with TipRanks
Follow Us
Novonesis (NVZMY)
OTHER OTC:NVZMY
NVZMY Stock Chart & Stats
$63.41
-$0.61(-1.09%)
At close: 4:00 PM EST
$63.41
-$0.61(-1.09%)
Day’s Range― - ―
52-Week Range$55.53 - $75.69
Previous CloseN/A
Volume8.66K
Average Volume (3M)1.56K
Market Cap
$29.58B
Enterprise Value$27.76B
Total Cash (Recent Filing)$310.49M
Total Debt (Recent Filing)$3.12B
Price to Earnings (P/E)87.8
Beta0.20
Next Earnings
Feb 25, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)0.47
Shares Outstanding414,555,050
10 Day Avg. Volume2,114
30 Day Avg. Volume1,559
Financial Highlights & Ratios
PEG Ratio-15.01
Price to Book (P/B)10.13
Price to Sales (P/S)29.52
P/FCF Ratio171.45
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda8.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Emerging Markets GrowthStrong growth in emerging markets indicates Novonesis's ability to capture new opportunities and expand its market presence, supporting long-term revenue growth.
Innovative Product LaunchesThe launch of new products enhances Novonesis's competitive edge and diversifies its offerings, which can drive sustained growth and market leadership.
EBITDA Margin ImprovementImproved EBITDA margins reflect operational efficiency and cost management, which can enhance profitability and provide financial stability.
Bears Say
Revenue DeclineA decline in revenue growth poses a risk to Novonesis's future profitability and market competitiveness, necessitating strategic adjustments.
Free Cash Flow DeclineDecreasing free cash flow limits Novonesis's ability to invest in growth opportunities and may strain financial flexibility over time.
Beverage Segment DeclineThe decline in the Beverage segment highlights challenges in maintaining market share, which could affect overall revenue and growth prospects.
Novonesis News
NVZMY FAQ
What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was $55.53 and its highest was $75.69 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is $29.58B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s upcoming earnings report date is Feb 25, 2026 which is in 9 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on Nov 06, 2025. The company reported $0.473 earnings per share for the quarter, missing the consensus estimate of $0.638 by -$0.165.
Is Novonesis overvalued?
According to Wall Street analysts Novonesis’s price is currently Overvalued.
Does Novonesis pay dividends?
Novonesis pays a Semiannually dividend of $0.35 which represents an annual dividend yield of 1.51%. See more information on Novonesis dividends here
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.92.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of $0.473 in its last earnings report, missing expectations of $0.638. Following the earnings report the stock price went up 7.537%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in NVZMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novonesis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Novonesis
Novonesis (NVZMY) is a technology-driven company specializing in innovative solutions for the healthcare and life sciences sectors. The company focuses on developing advanced biotechnology products and services aimed at improving patient outcomes and enhancing operational efficiencies within medical institutions. Novonesis is known for its cutting-edge research and development in drug delivery systems, diagnostic tools, and personalized medicine, positioning itself as a leader in the biopharmaceutical landscape.
NVZMY Company Deck
NVZMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a largely positive outlook with strong organic growth, particularly in emerging markets, and a robust pipeline of innovative products. However, challenges such as currency headwinds, the impact of exiting certain countries, and declines in the Beverage segment were noted.View all NVZMY earnings summariesNVZMY Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health
Technical Analysis
International Flavors & Fragrances
―
LyondellBasell
―
PPG Industries
―
RPM International
―
DuPont de Nemours
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---